Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix Health plc RNS Release

Director's dealing


RNS Number : 6755D
OptiBiotix Health PLC
01 February 2018
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Director's dealing

 

OptiBiotix  Health  p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, high cholesterol, diabetes was notified today that Neil Davidson, Non-Executive Chairman of the Company, today acquired 165,000 ordinary shares in the Company via his SIPP, representing 0.21% of the Company's issued share capital, at a price of 60 pence per share.

 

Previously to this notification Mr Davidson did not hold any shares in the Company.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Mark Collingbourne, Chief Financial Officer.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

Cairn Financial Advisers LLP

Tel: 020 7213 0880

Liam Murray / Jo Turner

 

 

 

finnCap Broker

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

 

Tony Quirke (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001

     

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Neil Davidson

2

Reason for notification

 

a.

Position/Status

Non-Executive Chairman

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Ordinary shares
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

  Purchase of ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

 

60 pence

 

165,000

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

165,000

 

60 pence

e.

Date of the transaction

1 February 2018

f.

Place of the transaction

AIM

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHZFLFBVLFLBBB

OptiBiotix Health plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use